findmyKOL

Erin Alesi, MD

Basic profile

Virginia Cancer Institute

ORCIDNone on fileNPI
RegionRichmond, VA · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Erin Alesi is an Oncology physician affiliated with Virginia Cancer Institute. OpenAlex indexes 24 publications with 3,963 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
24publications

Distinct works indexed by OpenAlex.

3,963citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1250 E Marshall St
Internal Medicine
Richmond, VA 232985051

Telephone

804-828-7999

Registry record last updated 1 Aug 2014.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    31.6%
    Phenothiazine15.3%
    Prochlorperazine Maleate100%
    Part D31 patients
    Opioid Agonist9%
    Oxycodone Hcl100%
    Part D13 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    22.3%
    Serotonin-3 Receptor Antagonist12.4%
    Ondansetron Hcl100%
    Part D34 patients
    H2 blocker6.2%
    Famotidine100%
    Part D11 patients

    + 1 more class in this area

  • Cancer & immunology

    13.3%
    Kinase inhibitor6.5%
    Tagrisso100%
    Part D<11 patients
    Aromatase Inhibitor3.7%
    Letrozole100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)63.7% facility · 36.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”